

Kazunori Murata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5229873/publications.pdf>

Version: 2024-02-01

19
papers

381
citations

933447

10
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

627
citing authors

#	ARTICLE	IF	CITATIONS
1	Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. <i>Environmental Health Perspectives</i> , 2021, 129, 17003.	6.0	15
2	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	4.6	50
3	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	7.1	63
4	Immunotyping Provides Equivalent Results to Immunofixation in a Population with a High Prevalence of Monoclonal Gammopathies. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1551-1560.	1.3	2
5	Pesticide use and kidney function among farmers in the Biomarkers of Exposure and Effect in Agriculture study. <i>Environmental Research</i> , 2021, 199, 111276.	7.5	17
6	Complex biological patterns of soluble cytokines and CD163 in childhood necessitating age-specific reference intervals for evidence-based clinical interpretation. <i>Clinical Biochemistry</i> , 2021, 98, 35-41.	1.9	1
7	Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1476-1483.	1.3	4
8	Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry. <i>Clinical Biochemistry</i> , 2020, 77, 57-61.	1.9	3
9	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	1.4	1
10	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	7.1	57
11	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 3127-3127.	1.4	2
12	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	1.4	34
13	Data from the analytical performance of the Abaxis Piccolo Xpress point of care analyzer in whole blood, serum, and plasma. <i>Data in Brief</i> , 2018, 16, 81-89.	1.0	4
14	Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. <i>Clinical Biochemistry</i> , 2018, 51, 66-71.	1.9	49
15	The Case for Laboratory Developed Procedures. <i>Academic Pathology</i> , 2017, 4, 2374289517708309.	1.1	24
16	Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms. <i>Scientific Reports</i> , 2016, 6, 22760.	3.3	4
17	Development of an Assay for Methotrexate and Its Metabolites 7-Hydroxy Methotrexate and DAMPA in Serum by LC-MS/MS. <i>Methods in Molecular Biology</i> , 2016, 1383, 213-222.	0.9	9
18	Analytical performance of the Abaxis Piccolo Xpress [®] point of care analyzer in whole blood, serum, and plasma. <i>Clinical Biochemistry</i> , 2015, 48, 1344-1346.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 169-175.	2.3	30